The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...
Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Olema Oncology (OLMA) to $25 from $30 but keeps an Outperform rating on ...
Topline results from the VERITAC-2 study showed that Arvinas-partnered vepdegestrant was able to extend progression-free survival (PFS) compared to the older degrader fulvestrant in a subset of HR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback